We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

236 hedge funds and large institutions have $722M invested in Rocket Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 112 increasing their positions, 41 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 41

172% more call options, than puts

Call options by funds: $3.92M | Put options by funds: $1.44M

37% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 35

5% more funds holding

Funds holding: 225 → 236 (+11)

2% less ownership

Funds ownership: 103.11% → 101.11% (-2%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

48% less capital invested

Capital invested by funds: $1.38B → $722M (-$655M)

Holders
236
Holders Change
+11
Holders Change %
+4.89%
% of All Funds
3.16%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
48
Increased
112
Reduced
41
Closed
35
Calls
$3.92M
Puts
$1.44M
Net Calls
+$2.48M
Net Calls Change
+$2.67M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$14.4M
2
BBA
Baker Bros. Advisors
New York
+$9.88M
3
SCM
Suvretta Capital Management
New York
+$9.24M
4
NCM
Nantahala Capital Management
Connecticut
+$6.22M
5
MB
MPM BioImpact
Massachusetts
+$5.91M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$25.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$19.7M
3
BCM
Boxer Capital Management
California
-$18.4M
4
ACA
Avoro Capital Advisors
New York
-$15.1M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$13.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nordea Investment Management
51
Nordea Investment Management
Sweden
$1.67M +$1.26M +127,135 +100%
HWAM
52
Hennion & Walsh Asset Management
New Jersey
$1.66M +$119K +12,027 +5%
ACM
53
ADAR1 Capital Management
Texas
$1.61M +$300K +30,400 +14%
Citigroup
54
Citigroup
New York
$1.56M +$1.09M +110,763 +90%
IC
55
Ikarian Capital
Texas
$1.48M – – –
Bank of New York Mellon
56
Bank of New York Mellon
New York
$1.4M +$156K +15,785 +8%
SFI
57
Susquehanna Fundamental Investments
Pennsylvania
$1.37M +$2.03M +205,378 New
MCP
58
Mirador Capital Partners
California
$1.36M +$1.18M +119,300 +141%
ECM
59
ExodusPoint Capital Management
New York
$1.34M +$107K +10,805 +6%
Qube Research & Technologies (QRT)
60
Qube Research & Technologies (QRT)
United Kingdom
$1.31M +$1.93M +195,793 New
UBS AM
61
UBS AM
Illinois
$1.23M +$446K +45,120 +32%
Mirae Asset Global ETFs Holdings
62
Mirae Asset Global ETFs Holdings
Hong Kong
$1.19M +$5.59K +566 +0.3%
N
63
Nuveen
North Carolina
$1.19M +$104K +10,577 +6%
HCA
64
Harbor Capital Advisors
Illinois
$1.19M +$130K +13,109 +8%
Barclays
65
Barclays
United Kingdom
$1.11M -$663K -67,070 -29%
AQR Capital Management
66
AQR Capital Management
Connecticut
$1.09M +$966K +97,758 +148%
TD Asset Management
67
TD Asset Management
Ontario, Canada
$1.09M -$156K -15,744 -9%
Rafferty Asset Management
68
Rafferty Asset Management
New York
$1.04M -$3.8K -385 -0.2%
Manulife (Manufacturers Life Insurance)
69
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.03M +$21.7K +2,198 +1%
Swiss National Bank
70
Swiss National Bank
Switzerland
$1.03M – – –
Hudson Bay Capital Management
71
Hudson Bay Capital Management
Connecticut
$1.01M +$372K +37,700 +33%
NLVP
72
New Leaf Venture Partners
New York
$1.01M – – –
PA
73
Perceptive Advisors
New York
$939K -$2.35M -237,858 -63%
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$893K -$242K -24,545 -15%
Susquehanna International Group
75
Susquehanna International Group
Pennsylvania
$857K +$778K +78,751 +158%
1 2
3
4 5

RCKT Hedge Fund Activity: Q1 2025 in Review

236 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2025, worth a combined $722M — down 48% from $1.38B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new RCKT positions and 35 closed out — a net gain of 13 holders — while 112 added to existing stakes and 41 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $14.4M. The largest seller was Citadel Advisors, cutting an estimated $25.8M.

  • 236 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2025, up from 225 in Q4 2024.
  • Funds reported $722M of Rocket Pharmaceuticals stock for Q1 2025, down 48% quarter-over-quarter.
  • 48 funds opened new Rocket Pharmaceuticals positions in Q1 2025 and 35 closed out, a net change of +13 holders.
  • The largest Rocket Pharmaceuticals buyer in Q1 2025 was Morgan Stanley, an estimated $14.4M added.
  • The largest Rocket Pharmaceuticals seller in Q1 2025 was Citadel Advisors, an estimated $25.8M sold.

Based on aggregated 13F filings for Q1 2025.